Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONWARD: Long-Term Extension Study of Higher Dose Nusinersen in SMA
NCT04729907Phase 3Completed
- Sponsor
- Biogen
- Start
- Apr 2021
- Primary completion
- Jul 2026
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 16
01
Overview
A Phase 3 trial of nusinersen in spinal muscular atrophy (SMA), sponsored by Biogen. Started Apr 2021; status: completed.
02
Drugs
nusinersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT04729907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04729907.